The biotechnology company, Cogent Biosciences, focuses on rational drug discovery and development to address the underlying causes of diseases. Their lead therapeutic candidate, bezuclastinib (CGT9486), is a precision kinase inhibitor designed to target the KIT D816V mutation, which drives Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST). By leveraging validated biology, Cogent aims to provide real hope for patients by developing precision therapies that treat the true drivers of disease.